Changemakers from over 46 countries met in Zermatt / 8th Zermatt Summit 2019 - Humanizing Globalization - Entrepreneurship to serve the common good
mehr
Storys aus Lausanne
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®
Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...
mehrSOPHiA GENETICS Expands Executive Team With a Chief Marketing Officer and New Chief Information Officer
Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Gaëtan Fraikin and Sergei Yakneen have joined its executive team as Chief Marketing Officer and Chief Information Officer, respectively. Mr. Fraikin and Mr. Yakneen bring decades of highly ...
mehrNewly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For 'Complete Clearance' of Symptoms and Consider Combination Therapy For Severe Patients
Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Lausanne, Switzerland (ots/PRNewswire) - Published online in the British Journal of ...
mehrDebiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the completion of the two-year follow-up period of its double-blind, randomized Phase II study of Debio 1143 in high-risk, previously untreated ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Sex education: Why school and parents should work together
Bern (ots) - There is an ongoing debate in society about sex education. Now a study funded by the Swiss National Science Foundation suggests that the best approach is a combination of parents and school. And that using friends and the internet as main sources of information on sexuality can cause problems. Sex education in school remains a controversial subject. That's why Yara Barrense-Dias, researcher on adolescent ...
mehr
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Lausanne, Switzerland (ots/PRNewswire) - ADC Therapeutics, an oncology drug discovery and development company that specializes in the development ...
mehrLigneSante Offers a Secure Communication Platform to Revolutionize Healthcare
A community of medical professionals sharing ideas and solving problems Lausanne, Switzerland (ots/PRNewswire) - LigneSante (https://lignesante.com/) today announced their online communication platform for healthcare professionals. The desire to connect to a collective knowledge around the management of diseases, aware that very often the complexity of medical ...
mehrThe list of speakers at the Zermatt Summit is impressive / 8th Zermatt Summit - September 12 - 14, 2019 in Zermatt
mehrDebiopharm and BIOASTER join forces to expand research to combat infectious diseases
Lausanne, Switzerland and Lyon, France (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in infectiology and microbiology, announced today having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. ...
mehrNew sustainable business models are changing society, bringing hope and creating new jobs / 8th Zermatt Summit - 12th - 14th September 2019 in Zermatt
mehrIMD World Competitiveness Ranking: Singapore topples United States as world's most competitive economy
mehr
Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Building-integrated photovoltaics: aesthetic, efficient and widely accepted
Bern (ots) - Within the scope of National Research Programme"Energy Turnaround" (NRP 70), researchers studied photovoltaic systems integrated into the roofs and façades (BIPV) of existing buildings from the point of view of aesthetic, ecological and economic criteria. Their findings: all developers and architects could use this technology for the renovation of ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Photography: A fresh look at science
Bern (ots) - The 457 entries submitted to the third SNSF Scientific Image Competition jury are online. They offer a behind-the-scenes look at research through stunning images and intriguing videos. The international jury awarded prizes to 15 entries that will be exhibited at the Biel/Bienne Festival of Photography. Now in its third edition, the SNSF Scientific Image Competition has collected more than 1200 photographs and ...
mehr#RosaceaNoFilter: Online Influencers Take the Lead in Raising Rosacea Awareness in Galderma's Empowering Rosacea Awareness Month Social Media Campaign
As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond the visible impact of living with this ...
mehrDebiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America
Lausanne, Switzerland (ots) - Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights. Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a ...
mehrSOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine
San Francisco (ots/PRNewswire) - SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest ...
mehr
SAKK - Swiss Group for Clinical Cancer Research
The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor, has awarded its science prize for the ninth time.
mehrSchweizerischer Nationalfonds / Fonds national suisse
SNSF image competition 2019: Participate and share unexpected insights into science
Bern (ots) - Following the success of the first two editions, the Swiss National Science Foundation has decided to stage its competition for images and short videos from the world of science for a third time. The best entries will be showcased in various exhibitions and via social media. The over 800 entries in 2017 and 2018, and the enthusiasm generated among the ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence
mehrTetra Pak Achieves 50% Renewable Electricity Consumption in Just Two Years Since RE100 Commitment
Lausanne, Switzerland (ots/PRNewswire) - Tetra Pak now obtains half of its global electricity supply from renewable sources, putting the company firmly on course to meet its RE100 commitment of using only renewable electricity across all global operations by 2030. (Logo: https://mma.prnewswire.com/media/632361/Tetra_Pak_Logo.jpg ) (Photo: ...
mehrTetra Pak Index 2018 Says Smart Packaging Offers Exciting Opportunities in Fast Growing Online Grocery
Lausanne, Switzerland (ots/PRNewswire) - Smart packaging technologies based on unique digital codes will take both online and off-line grocery in exciting new directions during the next few years, says the Tetra Pak Index 2018, launched today. (Logo: https://mma.prnewswire.com/media/632361/Tetra_Pak_Logo.jpg ) ...
mehrGalderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'
Lausanne, Switzerland (ots/PRNewswire) - Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve 'clear' (IGA 0) skin*. In the form of ...
mehr
The US overtakes Hong Kong at first place among world's most competitive economies
mehrDebiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections
Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...
mehrDebiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com
mehrEMA grants Orphan Drug Designation to Debiopharm International SA's FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer
Lausanne (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1347 for treatment of Biliary Tract Cancer affecting around ...
mehrDebiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Lausanne, Switzerland (ots) - The clinical trial is in collaboration with the Merck-Pfizer Alliance Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the dosing of the first patient in a Phase Ib study of Debio ...
mehrArbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)
Atlanta, GA, USA and Lausanne, Switzerland (ots) - Triptodur(TM), (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Arbor Pharmaceuticals, LLC, a U.S. based specialty ...
mehr
Vorherige12345678Nächste